News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Endocyte, Inc. Raises $75M, Gains 12% After Cutting Price
February 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Feb. 4 (Bloomberg) -- Endocyte Inc., a developer of drugs for ovarian and lung tumors, raised $75 million in its initial public offering after cutting the price twice this week for a total reduction of as much as 60 percent.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
IPO
Swiss ADC Biotech Takes SPAC Track to NASDAQ
April 23, 2025
·
1 min read
·
Annalee Armstrong
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
April 23, 2025
·
1 min read
·
Dan Samorodnitsky
Deals
Unusual New Fund Launches to Unlock Some $30B of Capital ‘Trapped’ in Public Biotechs
April 18, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer
April 16, 2025
·
1 min read
·
Dan Samorodnitsky
